Back to News
Market Impact: 0.4
CHMP Backs Ionis TRYNGOLZA For Severe Hypertriglyceridemia In Europe
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Ionis Pharmaceuticals said the EMA’s CHMP recommended approval of TRYNGOLZA (olezarsen) for adults with severe hypertriglyceridemia. The recommendation is a positive regulatory milestone, but the article does not report final European Commission approval or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
IONS0.75
More News
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated